Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

scPharmaceuticals Inc. - Common Stock (NQ:SCPH)

5.610 -0.020 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about scPharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >
Unusual volume stocks in Friday's session
Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMXI, HBI, VTLE, SCPH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
From Brodsky & Smith LLC
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Insights Ahead: scPharmaceuticals's Quarterly Earnings
 
Via Benzinga
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion. 
Via Stocktwits
Earnings Scheduled For November 13, 2024
 
Via Benzinga
scPharmaceuticals's Earnings Outlook
 
Via Benzinga
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity. 
Via Benzinga
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Which stocks are moving before the opening bell on Monday?
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals. 
Via Stocktwits
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
SCPH Revenue Up 99%
Via The Motley Fool
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Analyst Expectations For scPharmaceuticals's Future
 
Via Benzinga
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From scPharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Earnings Scheduled For March 19, 2025
 
Via Benzinga
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
From scPharmaceuticals Inc.
Via GlobeNewswire
SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024
SCPH stock results show that scPharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance... 
Via Benzinga
7 Short-Squeeze Stocks That Could Beat Down the Bears
Panic can be a cruel emotion, especially when the consequences are uncapped red ink. 
Via InvestorPlace
SCPH Stock Earnings: scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024
SCPH stock results show that scPharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.